Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand, and Gene and cell therapy

Sectors: Pharmaceutical

Unlocking the Power of the Genome At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of …

Sectors: Biotechnology

Illumina for Startups supporting genomics and multi-omics startups across the globe. Illumina for Startups Network aims to inspire the creation, funding, and growth of genomics and multi-omics startups across the globe. It is designed for the entrepreneurial ecosystem and focused on building connections, strengthening community, and advancing breakthrough genomics applications. Current Illumina for Startups initiatives include Startups Grants for founders to work with Illumina sites to run proof-of-concept sequencing experiments. For more information visit https://www.illumina.com/company/illumina-for-startups.html Past initiatives include Illumina Accelerator, company creation engine co-located with Illumina research and development sites in San Francisco Bay Area and Cambridge, UK. Illumina Accelerator …

Sectors: Biotechnology Startup accelerator & VC

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio Pharmaceutical, Biopharmaceutical, Innovation, Research and development, and Global business

Sectors: Pharmaceutical

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, …

Tags: DAX30 Sectors: Biotechnology Pharmaceutical

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse …

Sectors: Pharmaceutical

[Automatic translation follows] 14 varied and complementary establishments are the Paris-Saclay University: 3 universities *, 4 grandes écoles ** and 7 research organizations ***. In total, we represent 48,000 students, 9,000 researchers and teacher-researchers, 4,600 doctoral students and 275 laboratories. 14 Various goal complementary institutions Make up University Paris-Saclay: 3 universities *, 4 Prestigious University-Level Colleges ** and 7 Research Organizations ***. WE represent 9,000 profits and researchers, 4,600 PhD Students, 275 Laboratories and 48,000 students. * University Paris-Sud, University Versailles St-Quentin-en-Yvelines and University of Evry. ** Graduate School Optical Institute, Agroparistech, CentralsUpelec, Normal School Paris-Saclay. *** CEA, CNRS, IHES, …

Sectors: Research